A Randomized, Double-Blind, Third-Party-Unblinded, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD6423 in Healthy Volunteers
Latest Information Update: 02 Jun 2014
At a glance
- Drugs AZD 6423 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Apr 2014 Status changed from recruiting to completed as reoprted by ClinicalTrials.gov.
- 01 Nov 2013 New trial record